Zoliflodacin, A Novel Antimirobial Agent Against neisseria Gonorhoeae: A Systematic Rreview of Quasi-Experimental Studies
Downloads
Background: The gram-negative bacteria Neisseria gonorrhoeae is the source of the STI known as gonorrhea. N. gonorrhoeae can adapt well to humans as a host and become a pathogen with sophisticated mechanisms to avoid the innate immune response as well as suppress the adaptive immune response. Lately, zoliflodacin was shown to have antibacterial activity against N. gonorrhoeae. Purpose: The aim of this study is to evaluate the antibacterial activity of zoliflodacin against N. gonorrhoeae. Methods: We followed the PRISMA 2020 guidelines to systematically search and collect literature in the following databases: ProQuest, EBSCOhost, PubMed, ScienceDirect, Taylor&Francis, SAGE, JSTOR, and Wiley, without time limitation (until October 9th, 2022). Titles and abstracts were reviewed for relevance. The inclusion criteria were original article written in English that investigated the effects of zoliflodacin in patients with gonorrhea. From 177 studies, we retrieved five studies for this study, published between 2015 and 2021. Results: Zoliflodacin was highly active in vitro against N. gonorrhoeae isolates from European countries, China, Thailand, and South Africa, and also showed potent antimicrobial activity against multi-resistant N. gonorrhoeae isolates in South Korea. There were three different kinds of minimum inhibitory concentration (MIC) evaluated, with the following results: modal MIC (0.064-0.25 μg/mL), MIC50 (0.03-0.125 μg/mL), and MIC90 (0.06-0.25 μg/mL). There was no cross-resistance to antimicrobials currently or previously used for gonorrhea treatment. This MIC range could be used for further studies.
Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al. Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation. Clinical Infectious Diseases. 2018 Aug 1;67(4):504–12.
Vincent LR, Jerse AE. Biological feasibility and importance of a gonorrhea vaccine for global public health. Vaccine. 2019 Nov;37(50):7419–26.
Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. The Lancet Microbe. 2021 Nov;2(11):e627–36.
Unemo M, Golparian D, Eyre DW. Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea. In: Christodoulides M, editor. Neisseria gonorrhoeae [Internet]. New York, NY: Springer New York; 2019 [cited 2022 Aug 4]. p. 37–58. (Methods in Molecular Biology; vol. 1997). Available from: http://link.springer.com/10.1007/978-1-4939-9496-0_3
Kreisel KM, Weston EJ, St. Cyr SB, Spicknall IH. Estimates of the Prevalence and Incidence of Chlamydia and Gonorrhea Among US Men and Women, 2018. Sexual Trans Dis. 2021Apr;48(4):222–31.
O'Donnell J, Lawrence K, Vishwanathan K, Hosagrahara V, Mueller JP. Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. Antimicrob Agents Chemother. 2019 Jan;63(1):e01808-18.
Taylor SN, Marrazzo J, Batteiger BE, Hook EW, Seña AC, Long J, et al. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. N Engl J Med. 2018 Nov 8;379(19):1835–45.
Le W, Su X, Lou X, Li X, Gong X, Wang B, et al. Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e00863-20.
Luong ND. In Vitro Susceptibility to Zoliflodacin and Solithromycin in Neisseria gonorrhoeae Isolated in the Republic of Korea from 2016 to 2018. :53.
Jacobsson S, Kularatne R, Kittiyaowamarn R, Maseko V, Paopang P, Sangprasert P, et al. High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical Neisseria gonorrhoeae Isolates from Thailand and South Africa. Antimicrob Agents Chemother. 2019 Dec;63(12):e01479-19.
Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, et al. Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother. 2016 Jan;60(1):621–3.
Unemo M, Ringlander J, Wiggins C, Fredlund H, Jacobsson S, Cole M. High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014. Antimicrob Agents Chemother. 2015 Sep;59(9):5220–5.
Lin EY, Adamson PC, Klausner JD. Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions. Drugs. 2021 Jul;81(10):1153–69.
Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, et al. Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015 Mar;59(3):1478–86.
Taylor SN, Marrazzo J, Batteiger BE, Hook EW, Seña AC, Long J, et al. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. N Engl J Med. 2018 Nov 8;379(19):1835–45.
Copyright (c) 2024 Berkala Ilmu Kesehatan Kulit dan Kelamin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
